Brokerages expect Myriad Genetics, Inc. (NASDAQ:MYGN) to post sales of $182.22 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Myriad Genetics’ earnings, with the lowest sales estimate coming in at $181.80 million and the highest estimate coming in at $183.02 million. Myriad Genetics posted sales of $177.50 million in the same quarter last year, which suggests a positive year over year growth rate of 2.7%. The firm is scheduled to announce its next earnings results on Tuesday, November 7th.

On average, analysts expect that Myriad Genetics will report full year sales of $182.22 million for the current financial year, with estimates ranging from $759.00 million to $789.22 million. For the next financial year, analysts anticipate that the firm will post sales of $801.06 million per share, with estimates ranging from $750.61 million to $828.90 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Myriad Genetics.

Myriad Genetics (NASDAQ:MYGN) last issued its earnings results on Tuesday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.26 by $0.04. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The firm had revenue of $200.50 million for the quarter, compared to analysts’ expectations of $193.71 million. During the same quarter last year, the company posted $0.36 earnings per share. Myriad Genetics’s revenue was up 7.5% on a year-over-year basis.

A number of analysts recently weighed in on MYGN shares. BidaskClub raised shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Saturday, August 12th. Zacks Investment Research raised shares of Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a research note on Monday, July 17th. Barclays PLC lowered their target price on shares of Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 9th. Cowen and Company reissued a “hold” rating and issued a $25.00 target price on shares of Myriad Genetics in a research note on Monday, August 14th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $23.00 target price (up previously from $21.00) on shares of Myriad Genetics in a research note on Thursday, August 10th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the stock. Myriad Genetics has a consensus rating of “Hold” and a consensus price target of $21.22.

TRADEMARK VIOLATION NOTICE: “Brokerages Expect Myriad Genetics, Inc. (MYGN) Will Post Quarterly Sales of $182.22 Million” was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/19/brokerages-expect-myriad-genetics-inc-mygn-will-post-quarterly-sales-of-182-22-million.html.

Myriad Genetics (NASDAQ MYGN) opened at 33.05 on Tuesday. The firm has a 50-day moving average of $29.02 and a 200-day moving average of $23.38. Myriad Genetics has a one year low of $15.15 and a one year high of $33.42. The company has a market cap of $2.26 billion, a PE ratio of 103.61 and a beta of 0.26.

In other Myriad Genetics news, Director John T. Henderson sold 30,000 shares of the business’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $30.30, for a total value of $909,000.00. Following the transaction, the director now directly owns 52,524 shares in the company, valued at $1,591,477.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. 6.20% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new position in Myriad Genetics in the second quarter valued at about $101,000. Riverhead Capital Management LLC boosted its position in Myriad Genetics by 80.9% in the second quarter. Riverhead Capital Management LLC now owns 4,161 shares of the company’s stock valued at $107,000 after buying an additional 1,861 shares in the last quarter. Ameritas Investment Partners Inc. acquired a new position in Myriad Genetics in the first quarter valued at about $112,000. Fiduciary Trust Co. acquired a new position in Myriad Genetics in the second quarter valued at about $113,000. Finally, Ronald Blue & Co. LLC acquired a new position in Myriad Genetics in the second quarter valued at about $208,000.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Get a free copy of the Zacks research report on Myriad Genetics (MYGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.